Mural Oncology plc (MURA)

NASDAQ: MURA · Real-Time Price · USD

1.240

-0.020 (-1.59%)

At close: Apr 1, 2025, 4:00 PM

1.290

+0.050 (4.03%)

After-hours: Apr 1, 2025, 4:22 PM EDT

Mural Oncology Employees

Mural Oncology had 116 employees as of December 31, 2024. The number of employees decreased by 1 or -0.85% compared to the previous year.

Employees

116

Change (1Y)

-1

Growth (1Y)

-0.85%

Revenue / Employee

n/a

Profits / Employee

-$1,107,879

Market Cap

21.36M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	116	-1	-0.85%
Dec 31, 2023	117	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

MURA News

7 days ago - Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges - Benzinga
7 days ago - Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer - GlobeNewsWire
21 days ago - Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - GlobeNewsWire
6 weeks ago - Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
2 months ago - Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts - GlobeNewsWire
4 months ago - Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
4 months ago - Mural Oncology Announces Publication Highlighting Promising Clinical Antitumor Activity Shown in its ARTISTRY-1 Clinical Trial of Nemvaleukin, its Lead Engineered Fusion Protein, in the Journal for ImmunoTherapy of Cancer - GlobeNewsWire
5 months ago - Mural Oncology to Participate in Two Upcoming Investor Conferences - GlobeNewsWire